USP seeks stakeholder feedback on the proposed USP Drug Classification 2017 (USP DC) -- an independent drug classification system currently under development by the USP Healthcare Quality Expert Committee.
The USP DC addresses stakeholder needs emerging from the extended use of the USP Medicare Model Guidelines (USP MMG) beyond the Medicare Part D benefit.
As part of their draft process, the expert committee encourages public review and comment. Those comments will be considered in the final determination of USP DC 2017.
Comment deadline is December 5, 2016.
Visit the USP DC page to learn more and submit your comments.